Nkolika Jacinta Ezekwelu

Dr. Nkolika Jacinta Ezekwelu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
AEAdaeze E. Egwudo
Adaeze E. Egwudo
Ayodapo JegedeAyodapo Jegede
Ayodapo Jegede
TOTolulope A. Oyeniyi
Tolulope A. Oyeniyi
NENkolika Jacinta Ezekwelu
Nkolika Jacinta Ezekwelu
SASamirah N. Abdu-Aguye
Samirah N. Abdu-Aguye
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Integrating digital health technologies (DHTs) in Nigeria’s healthcare system holds promise, yet the opportunities, challenges, and strategies influencing their success remain insufficiently explored. This scoping review aimed to map these factors, focusing on healthcare settings in Nigeria. A comprehensive search of databases (PubMed, Scopus, Web of Science, and CINAHL) and Google Scholar identified publications on DHT use in Nigeria from July 1, 2014, to June 30, 2024. A total of 31 observational and experimental studies were included involving healthcare workers, patients, caregivers, or other stakeholders impacted by DHT integration. Key findings revealed that DHTs enhanced treatment adherence, healthcare utilization, and community engagement while expanding technology infrastructure for scaling interventions. Notable opportunities included support and training and improved data quality. However, challenges such as operational and logistical barriers, inadequate network coverage, and cultural and gender sensitivity issues were prevalent. Strategies to address these challenges focused on continuous training for healthcare workers, community involvement to foster engagement, and data reporting and quality improvements. Despite their potential to transform healthcare delivery, particularly in underserved areas, successful integration of DHTs in Nigeria requires addressing infrastructure gaps, cultural norms, and operational challenges. Community engagement, capacity building for healthcare workers, and data-driven decision-making are critical to maximizing the impact of digital health interventions in Nigeria.

AOAzuka Patrick Okwuraiwe
Azuka Patrick Okwuraiwe
COChizaram A. Onyeaghala
Chizaram A. Onyeaghala
OOObiageli Theresa Ozoude
Obiageli Theresa Ozoude
MSMuritala Suleiman
Muritala Suleiman
SASamirah Abdu-Aguye
Samirah Abdu-Aguye
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Lassa fever (LF) is an acute viral hemorrhagic fever that poses a substantial public health security threat in West Africa. The non-specific clinical presentation of LF, coupled with a lack of reliable point-of-care diagnostics, means delayed diagnosis, leading to severe complications and mortality during epidemics. A systematic review and meta-analyses were performed by conducting an extensive online search using PubMed, Web of Science, Scopus, CINAHL, and Google Scholar (PROSPERO protocol identifier number CRD42024587426). Only peer-reviewed studies written in English were included in publications from 1 September 2014, to 31 August 2024. The analysis and reporting followed PRISMA guidelines. The quality of the included studies was assessed using the critical appraisal tools developed from the Joanna Briggs Institute Systematic Review Checklist for cohort studies. We included 19 studies that contained data from 4177 patients hospitalized with LF of any age. Most included studies employed a retrospective cohort design and were conducted in Nigeria (16/19; 84.2%). The mortality rate was highest in a Sierra Leonean study (63.0%), whereas a group-based analysis of Nigerian studies using a random-effects model identified Owo as having the highest mortality rate of 13% (95% CI: 6–23; I2 = 98%). The pooled mortality rate for severe LF was 19% (95% confidence interval [CI]:10–32). The most common complications of LF are acute kidney injury (AKI) at a pooled proportion of 19% (95% CI; 13–26; I2 = 89%)), followed by abnormal bleeding at a pooled proportion of 17% (95% CI; 9–30; I2 = 98%), and central nervous system (CNS) dysfunction at a pooled proportion of 15% (95% CI; 6–32; I2 = 98%). With one out of every five hospitalized LF patients likely to die in West Africa, accelerating the development of rapid diagnostic tests, licensed vaccines, and novel therapeutics is crucial. Strengthening community engagement and risk communication, developing regional treatment guidelines, decentralizing LF care units, and training healthcare workers using a harmonized curriculum will enhance early diagnosis and effective case management, thereby reducing severe complications and mortality.